107 related articles for article (PubMed ID: 37667956)
1. Prognostic and predictive significance of GITR in metastatic renal cell carcinoma.
Balçık OY; Akın D; Ceylan GS; Demİr B; Aytaç A; Çulhacı N; Oktay E
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7781-7792. PubMed ID: 37667956
[TBL] [Abstract][Full Text] [Related]
2. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of immunological profile based on CD8+ and FoxP3+ T lymphocytes in the peritumoral and intratumoral subsites for renal cell carcinoma.
Teke K; Yaprak Bayrak B; Yuksekkaya M; Uslubas AK; Kosem ME; Yilmaz H; Kara O; Dillioglugil O
Int Urol Nephrol; 2020 Dec; 52(12):2289-2299. PubMed ID: 32761342
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
7. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
[TBL] [Abstract][Full Text] [Related]
8. Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.
Nocentini G; Alunno A; Petrillo MG; Bistoni O; Bartoloni E; Caterbi S; Ronchetti S; Migliorati G; Riccardi C; Gerli R
Arthritis Res Ther; 2014 Sep; 16(5):444. PubMed ID: 25256257
[TBL] [Abstract][Full Text] [Related]
9. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
10. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
[TBL] [Abstract][Full Text] [Related]
11. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
Jensen HK; Donskov F; Nordsmark M; Marcussen N; von der Maase H
Clin Cancer Res; 2009 Feb; 15(3):1052-8. PubMed ID: 19188179
[TBL] [Abstract][Full Text] [Related]
12. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
13. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
Verhaart SL; Abu-Ghanem Y; Mulder SF; Oosting S; Van Der Veldt A; Osanto S; Aarts MJB; Houtsma D; Peters FPJ; Groenewegen G; Van Herpen CML; Pronk LM; Tascilar M; Hamberg P; Los M; Vreugdenhil G; Polee M; Ten Tije AJ; Haanen JBAG; Bex A; van den Eertwegh AJ
Clin Genitourin Cancer; 2021 Jun; 19(3):274.e1-274.e16. PubMed ID: 33317946
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.
Gulturk I; Yilmaz M; Tacar SY; Tural D
Q J Nucl Med Mol Imaging; 2023 Sep; 67(3):223-229. PubMed ID: 34881845
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
17. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer patients as compared to tumor-negative lymph nodes.
Krausz LT; Fischer-Fodor E; Major ZZ; Fetica B
Int J Immunopathol Pharmacol; 2012; 25(1):59-66. PubMed ID: 22507318
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma.
Ishiyama Y; Kondo T; Tachibana H; Ishihara H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Tanabe K
Int J Clin Oncol; 2021 Mar; 26(3):552-561. PubMed ID: 33135126
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
Zhu MMT; Burugu S; Gao D; Yu J; Kos Z; Leung S; Horst BA; Nielsen TO
Mod Pathol; 2020 Sep; 33(9):1753-1763. PubMed ID: 32350416
[TBL] [Abstract][Full Text] [Related]
20. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.
Bianchini R; Bistoni O; Alunno A; Petrillo MG; Ronchetti S; Sportoletti P; Bocci EB; Nocentini G; Gerli R; Riccardi C
Eur J Immunol; 2011 Aug; 41(8):2269-78. PubMed ID: 21557210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
